Tuesday, October 22, 2019

QualityStocksNewsBreaks – INmune Bio, Inc.’s (NASDAQ: INMB) XPro1595 Highlighted During Press Conference at the Society for Neuroscience 49th Annual Meeting


INmune Bio (NASDAQ: INMB) on Monday announced that Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine, presented data that demonstrated the use of INmune Bio’s lead compound, XPro1595, to lessen the exacerbation of Alzheimer’s-like pathology brought on by a high fat and high fructose diet in mice. Dr. Tansey presented the data as the lead speaker at a press conference during the Society for Neuroscience 49th Annual Meeting in Chicago. “The new data strengthen our findings that a potential connection between diets rich in fat and sugar and chronic inflammation can lead to an increased risk for Alzheimer’s disease,” Dr. Malú Tansey stated in the news release. “With more than 93 million obese people in the U.S., according to the most recent data from the Centers for Disease Control and Prevention, understanding the link between obesity and Alzheimer’s disease is more relevant now than ever. By targeting inflammation with XPro1595 we may be able to effectively treat neurodegenerative diseases.”

To view the full press release, visit http://ibn.fm/DCqzc

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. For more information, visit the company’s website at www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: